For example, if an inhibitor targeting PRMT1 also inhibits PRMT5, it could disrupt normal immune responses or cell cycle control, which not only weakens the anti‐tumour effect but might also lead to serious side effects in patients. This evidence concerns the gene PRMT1 and neoplasm.